Trial · NCT06234592
The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
NCT06234592, Not applicable, Recruiting, King's College Hospital NHS Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock. Trials, record NCT06234592. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06234592
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock
- NCT number
- NCT06234592
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 45 participants, estimated
- Lead sponsor
- King's College Hospital NHS Trust
- Conditions
- Septic Shock, Acute Kidney Injury
- Interventions
- Angiotensin II, Vasopressin, Norepinephrine
- First posted
- 2024-01-31
- Last updated
- 2025-04-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cortical mean transit time (mTT) measured in seconds | Measured at +24 hours following study vasopressor infusion starting | Contrast enhanced ultrasound measure of renal cortical tissue blood flow |
| Secondary | Cortical mean transit time (mTT) measured in seconds | Measured at +1 hour and +24 hours following study vasopressor infusion starting | Contrast enhanced ultrasound measures of renal cortical tissue blood flow |
| Secondary | Cortical perfusion index (PI) measured in arbitrary units | Measured at +1 hour and +24 hours following study vasopressor infusion starting | Contrast enhanced ultrasound measures of renal cortical tissue blood flow |
| Secondary | Cortical wash in rate (WiR) measured in arbitrary units | Measured at +1 hour and +24 hours following study vasopressor infusion starting | Contrast enhanced ultrasound measures of renal cortical tissue blood flow |
| Secondary | Urinary oxygen tension (pO2) across 24 hours study period measured in millimetres of mercury (mmHg) | Across 24 hours study period | Mean urinary pO2 |
| Secondary | Tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7). Both measured in nanograms per millilitre (ng/ml) | Measured at baseline and +24 hours following study vasopressor infusion starting | Biomarker analysis - regulatory proteins involved in initiating cell cycle arrest and associated with AKI |
| Other | Perfused vessel density (PVD) measured in millimetres per square millimetre | Measured at +1 hour and +24 hours following study vasopressor infusion starting | Incident dark field video microscopy measures of the systemic microcirculation |
| Other | Microvascular flow index (MFI) (unitless score from 0 to 3 where 3 is the value see in health). | Measured at +1 hour and +24 hours following study vasopressor infusion starting | Incident dark field video microscopy measures of the systemic microcirculation |
| Other | Syndecan 1, angiopoietin 1 & 2, Interleukin 6 & 8 (IL-6, IL-8) and tissue necrosis factor (TNF). All measured in nanograms per millilitre (ng/ml) | Measured at baseline and +24 hours following study vasopressor infusion starting | Biomarker analysis - markers of inflammation and endothelial activation/function |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38870103 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06234592
GET https://conductscience.org/api/trials/v1/NCT06234592/registered